What changed
Moderna (MRNA) is trying to digest a strong fundamental update against a softer tape. On November 6, Moderna said third-quarter 2026 revenue grew 29% to $1.3 billion, cash costs fell 10% to $1.0 billion, and it was profitable, while raising full-year 2026 revenue guidance to 15% to 25% growth from a prior outlook of up to 10% growth. Piper Sandler followed on November 9 by lifting its price target to $305 from $230 and keeping an Overweight rating, citing third-quarter product sales of $1.27 billion and the higher revenue outlook. Goldman Sachs also raised its target to $195 on November 12 while staying Neutral, pointing to the same revenue beat and upside to consensus on EPS. îciteîturn0search0îturn0search1îturn0search2îturn0search3î
Price action and trend read
Against that backdrop, the stock is not in a clean breakout. MRNA last traded at $214.40 after a 2.34% 24-hour drop, with the recent session showing a range of $223.89 to $212.23. The share price is below the 7-day SMA of $224.11, the 20-day SMA of $234.48, the 12-day EMA of $228.54, and the 26-day EMA of $227.41. That keeps the short-term structure in distribution mode, even though the stock remains above the 50-day SMA of $219.39 by a narrow margin. îciteîturn0search1î
Key levels traders are watching
The most relevant pivot is $216.84. Above that, the first checkpoint is $221.45, then $228.50, which would start to repair the short-term trend and challenge the move back toward the 20-day average at $234.48. On the downside, immediate support sits at $209.79, with stronger support at $205.18. The Bollinger middle band is $234.48, the lower band is $199.04, and %B at 0.2167 shows the stock is still positioned in the lower part of its recent range rather than pressing the upper band. ATR(14) of $18.51 suggests swings remain wide enough that a single day can move through multiple levels quickly. îciteîturn0search1î
Derivatives positioning is slightly defensive
Binance perpetual futures are not flashing panic, but they are leaning cautious. Funding is neutral at 0.0000%, open interest is 15,951 contracts, and open interest value is $3.36 million, with 24-hour OI up 2.71%. The 1-hour global long/short ratio is 0.8734, and top-trader accounts are 47.3% long versus 52.7% short. That is a mild short bias, but not an extreme one. Taker flow is close to balanced at 1.0136, with buy volume of 457 against sell volume of 451, which argues against a one-sided momentum squeeze right now. îciteîturn0search1î
Scenario framing
If Moderna can reclaim the $221.45 to $228.50 zone, the chart would begin to absorb the recent decline and shift attention back toward the 20-day average. If it loses $209.79, the next area that matters is $205.18, with the Bollinger lower band at $199.04 as a broader mean-reversion reference. The current setup is less about a decisive trend call and more about whether the market wants to fade the post-earnings strength or rebuild a higher base after the guidance reset. îciteîturn0search1îturn0search2îturn0search3î



